Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Exploratory Study to Evaluate the Efficacy and Safety of HAD-B1 for Dose-Finding in EGFR Mutation Positive and Locally Advanced or Metastatic NSCLC Subjects Who Need Afatinib Therapy.

Integr Cancer Ther · 2021 · PMC8381462 · PMID 34409891

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

somewhat significantno p-value reported

At 6 weeks after administration, the decrease in the test group 1 and the control group at 12 weeks was somewhat significant, but there was no statistical significance between groups ( P = .4450 and .9015; Table 11 ).

also in 217 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.